2022
DOI: 10.3389/fbioe.2022.953555
|View full text |Cite
|
Sign up to set email alerts
|

The emerging role of cancer nanotechnology in the panorama of sarcoma

Abstract: In the field of nanomedicine a multitude of nanovectors have been developed for cancer application. In this regard, a less exploited target is represented by connective tissue. Sarcoma lesions encompass a wide range of rare entities of mesenchymal origin affecting connective tissues. The extraordinary diversity and rarity of these mesenchymal tumors is reflected in their classification, grading and management which are still challenging. Although they include more than 70 histologic subtypes, the first line-tr… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
17
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 16 publications
(17 citation statements)
references
References 115 publications
(121 reference statements)
0
17
0
Order By: Relevance
“…To make RCM1 administration more clinically relevant, we synthesized amphiphilic poly-beta amino ester (aPBAE) nanoparticles to use as a vehicle for RCM1 delivery. Nanoparticles have been used as a vehicle in the clinic for hydrophobic drugs like paclitaxel, as well as other RMS therapeutics like doxorubicin, and can be administered intravenously for several cancer types ( 60 , 61 ). The aPBAE is one of the polymers that is used in generating nanoparticles and has recently attracted enormous attention in gene or drug delivery due to its excellent biocompatibility and biodegradability ( 62 ).…”
Section: Discussionmentioning
confidence: 99%
“…To make RCM1 administration more clinically relevant, we synthesized amphiphilic poly-beta amino ester (aPBAE) nanoparticles to use as a vehicle for RCM1 delivery. Nanoparticles have been used as a vehicle in the clinic for hydrophobic drugs like paclitaxel, as well as other RMS therapeutics like doxorubicin, and can be administered intravenously for several cancer types ( 60 , 61 ). The aPBAE is one of the polymers that is used in generating nanoparticles and has recently attracted enormous attention in gene or drug delivery due to its excellent biocompatibility and biodegradability ( 62 ).…”
Section: Discussionmentioning
confidence: 99%
“…Furthermore, only one report compared the effects of pegylated liposomes loaded with doxorubicin and liposomal daunorubicin on the treatment of advanced-stage Kaposi’s sarcoma; unfortunately, and because of the power of the study, there is no sufficient evidence of the efficacy of these treatments [ 40 ]. More recently, strategies to delivery chemotherapeutic drugs used for sarcoma treatment have been developed [ 41 ]. One strategy is focus on the development of paclitaxel nanocrystal formulation to improve the water solubility properties of this hydrophobic drug [ 42 ].…”
Section: Discussionmentioning
confidence: 99%
“…In recent years, nanotechnology has shown potential in sarcoma treatment thanks to the development of smart materials and more effective drug delivery systems. Examples include effective docetaxel-loaded mPEG-PLA nanoparticles in sarcoma-bearing mice and albumin-paclitaxel (nab-paclitaxel/Abraxane™) in osteosarcoma mice ( 76 78 ). ( 79 ) Only four nano-drug delivery systems have been FDA-approved for sarcoma - Doxil (Caelyx) ® for AIDS-related Kaposi’s sarcoma, DaunoXome ® and Lipo-Dox ® for Kaposi’s sarcoma and Liposomal mifamurtide (MEPACT) for Osteosarcoma.…”
Section: Future Directionsmentioning
confidence: 99%